Baird raised the firm’s price target on Astrana Health (ASTH) to $40 from $37 and keeps an Outperform rating on the shares. The firm updated its model as it becomes more positive on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health files automatic mixed securities shelf
- Astrana Health details financial impact of PHP acquisition
- Astrana Health price target raised to $38 from $37 at Truist
- OBBBA Threatens Astrana Health’s Revenue as Tighter Eligibility Rules Shrink Federally Funded Patient Base
- Astrana Health: Conservative 2026 Outlook, Earnings Tailwinds, and Valuation Upside Support Buy Rating